Visit booth 707 to learn about the clinical studies behind ProNephro AKI™ (NGAL), the first FDA-cleared test for assessing AKI risk in ICU patients ≥3 months to
NGAL is a direct indicator of kidney damage that rises within 2 hours of injury, up to 3 days before serum creatinine responds, providing an earlier window for clinical intervention.
96% of healthcare professionals believe that early detection of AKI can lead to significantly better patient outcomes. By providing an additional data point for assessing kidney damage, ProNephro AKI helps clarify which patients to worry about so you can confidently take more appropriate action to manage fluids, avoid nephrotoxic agents, and potentially prevent permanent kidney damage.
bioporto.us